What Occurred On Tuesday That Caused IceCure (ICCM) Stock To Soar Pre-Market?


After the minimally invasive cryoablation technology supplier presented remarkable clinical trial findings, shares of IceCure Medical Ltd (NASDAQ: ICCM) soared 222.44% to $3.02 on Tuesday.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


What information did ICCM share?

Interim findings from the ICESECRET research for the treatment of those with small renal masses (“SRM”) who are not candidates for kidney-preserving surgery were released by IceCure (ICCM). On December 14, 2022, information was given at the Urological Association Conference in Eilat, Israel. Dr. Nasir Said of Bnai Zion Medical Center gave a presentation captioned “Renal Mass Cryoablation – Interim Analysis ICESECRET Study.”

Out of the 115 patients who were recruited, 107 patients (112 lesions) came for follow-up with a mean length of 22.8 months and a range of 12-60 months, according to the presentation. When the operation protocol was followed, an 89.5% recurrence-free rate was shown at a mean follow-up period of 22.2 months in a subset of patients with no previous record of kidney cancer within the same kidney and a lesion 3 cm.

At a mean follow-up of 16.5 months, the recurrence-free rate of 91 patients out of 107 patients including 13 patients who received a second cryoablation, was 85.1%. There were 5 serious adverse events reported, 4 of which had mild severity, were treated conservatively, and went away within 1 to 5 days. One serious complication occurred 7 months after the cryoablation process that caused the nephrectomy, in which there was a new early symptom of ipsilateral hydronephrosis.

Up to around 25 minutes, respectively, were spent performing cryoablation, and a 2-day hospital stay. Based on these preliminary findings, the IceCure briefing concluded that cryoablation is secure and efficient for treating renal tumors less than 5 cm.

What do these findings imply for ICCM?

ProSense is a valuable therapeutic option for interventional radiologists and urologists to use when patients are not candidates for surgery, as shown by the remarkable interim results by ICCM. The results will let IceCure (ICCM) continue to employ ProSense in the countries where its cryoablation technique is legal to use on benign and cancerous kidney tissues. The commercialization momentum is supported by the expanding amount of evidence on ProSense’s effectiveness and safety across a wide variety of indications, particularly in locations that profit from having a single device that can be utilized across many specialties.


Please enter your comment!
Please enter your name here